Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986263

Drug Profile

BMS 986263

Alternative Names: BMS986263; ND-L02-s0201

Latest Information Update: 15 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nitto Denko
  • Developer Bristol-Myers Squibb; Nitto Denko
  • Class Antifibrotics; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatic fibrosis; Idiopathic pulmonary fibrosis
  • Preclinical Liver cirrhosis
  • No development reported Fibrosis

Most Recent Events

  • 13 Jan 2020 Bristol-Myers Squibb plans a phase I trial for Hepatic impairment (In volunteers) in USA (IV) (NCT04225936)
  • 28 May 2019 Bristol-Myers Squibb completes a phase II trial in Hepatic fibrosis in USA (NCT03420768)
  • 09 Nov 2018 Safety, pharmacokinetics and immunogenicity data from a phase I trial in healthy volunteers presented at 69th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top